Out-licensing

Reperfusions can lead to severe damage in patients with heart attacks and strokes, the SOD-nanoparticles would be highly beneficial for use in hospitals for treating these patients.

Summary

Reperfusion injury occurs when blood is returned to the brain after a period of time where is has been restricted, often due to stroke or heart attack. The absence of oxygen and nutrients from blood often creates a condition where the restoration of circulation will result in inflammation and oxidative damage to the brain. Researchers at the University of Nebraska have developed a method in which powerful antioxidants, such as superoxidase dismutase (SOD) and catalase (CAT), are encapsulated by biodegradable nanoparticles that can readily cross the blood brain barrier. When SOD-nanoparticles were injected at the time of reperfusion, animals demonstrated improved neurological behavior and a 70% reduction in the total infarct volume. This indicates that the use of SOD-nanoparticles would be highly beneficial in use with patients that undergo reperfusion.

Market Value

• Crosses BBB Without Receptor Mediation
• Can Carry Multiple Antioxidative Enzymest 3
• Useful in Additional CNS Disorders Involving Oxidative Damage
• Cost Effective

Early Stage

US Patent Issued:

      7,332,159

US Patent Application Published:

      US-2008-0248118 A1

UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with University of Nebraska Medical Center.